Abstract:The prevalence of type-2 diabetes is rapidly increasing. Currently, exenatide is the first medicine which mimics incretin. However, it requires subcutaneous injection twice a day, an inconvenient way for patients. In this study, we identified a novel peptide with similar pharmacology to exenatide in rodents as GLP-1 receptor agonist which consists of 17 amino acids (17P). It promotes Ins-1 cell proliferation and insulin secretion and lowers blood glucose of diabetic rats. 17P was synthetized by solid-phase peptide synthesis. Interactions between GLP-1 receptor and 17P were studied by Bio-layer interferometry. Ins-1 cell proliferation was studied by MTT assay. ELISA was used to study Ins-1 cell insulin secretion. In vivo tests were performed with male Wistar rats. We used high fat diet and STZ injection to induce a type-2 diabetic rats model. Then, those rats were randomized to different test groups, and administered exenatide, 17P and saline water injection, to evaluate different responses. Based on HPLC (high performance liquid chromatography) and MS (mass spectrometry), 17P synthesis was successful. Bio-layer interferometry data showed a close interaction between GLP-1 receptor and 17P. 17P treatment of Ins-1 cells for 24 h could promote cell proliferation and insulin secretion in a dose-dependent manner. Administration of 17P in HF-STZ male Wistar rats demonstrated that 17P could lower the level of blood glucose and stabilize the body weight of the diabetic rats. All 17P treatments were similar to treatment with exenatide. In vitro and in vivo studies demonstrated that 17P could relieve symptoms of type-2 diabetes. Therefore, 17P could be developed as a promising type-2 diabetes therapeutic drug.

ScreeningandBioactivityofHigh-Activity Short-PeptideMimicsofExendin-4

Screening and Identification of A Targeting Peptide to Nglp-1r from Phage Display Peptide Library

The Potential DPP-4 Inhibitors from Xiao-Ke-An Improve the Glucolipid Metabolism Via the Activation of AKT/GSK-3β Pathway.

Bioactivity and Structure of Analogues of Exendin-4

Identifying glucagon-like peptide-1 mimetics using a novel functional reporter gene high-throughput screening assay.

[Cloning, Expressing of Exendin-4 Analogue and Bioactivity Analysis in Vivo].

Recombinant Lactococcus Lactis Expressing Bioactive Exendin-4 to Promote Insulin Secretion and Beta-Cell Proliferation in Vitro

Screening of a phage display library of exendin-4 mutants with the extracellular domain of rat GLP-1 receptor.

Heterologous Expression And Delivery Of Biologically Active Exendin-4 By Lactobacillus Paracasei L14

Exendin-4 Improves Glucose Metabolism in Insulin-Resistant Cells by Upregulating the Phosphorylative AMPK

Purification and bioactivity of exendin-4, a peptide analogue of GLP-1, expressed in Pichia pastoris

Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics.

Recent Development of Exendin-4 and Its Analogs

Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist

Effects of Glucagon-Like Peptide-1 Analogue (Exendin-4) on the Function of Β-Cell and Insulin Resistance in OLETF Diabetic Rats

Production of EW,a Recombinant Analogue of Exendin-4,by Genetic Engineering and Its in Vivo Hypoglycemic Activity Analysis

A Site-Specific PEGylated Analog of Exendin-4 with Improved Pharmacokinetics and Pharmacodynamics in Vivo

A Novel Peptide with Similar Pharmacology to Exenatide in Rodents As GLP-1 Receptor Agonist

Synthesis and bioactivity evaluation of dipeptidyl peptidase IV resistant glucagon-like peptide-1 analogues.

Site-specific Fatty Chain-Modified Exenatide Analogs with Balanced Glucoregulatory Activity and Prolonged in Vivo Activity.

In Vitro and in Vivo Characterization of a Novel Long-Acting GLP-1 Receptor Agonist, Exendin-4–Fc Fusion Protein